These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 23414095)

  • 21. [Prostaglandin treatment of ductus-dependent congenital heart defects].
    Olsson B; Björkhem G; Lundström NR
    Lakartidningen; 1984 Oct; 81(40):3619-22. PubMed ID: 6541738
    [No Abstract]   [Full Text] [Related]  

  • 22. [Therapeutic advances in neonatal cardiology].
    Salazar J; Burgueros M; Peŕez V
    An Esp Pediatr; 1983 Sep; 19 Suppl 18():37-45. PubMed ID: 6685984
    [No Abstract]   [Full Text] [Related]  

  • 23. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
    Kertész E; Hencz P; Tekulics P; Beviz J; Száva J; Matkó I; Kovács G
    Orv Hetil; 1980 May; 121(20):1197-9. PubMed ID: 7413203
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prostaglandin E2 in newborns with congenital heart disease].
    Schlemmer M; Khoss A; Salzer HR; Wimmer M
    Z Kardiol; 1982 Jul; 71(7):452-7. PubMed ID: 6958133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoids and hyperostosis.
    Helliwell PS; Cheesbrough M
    Br J Dermatol; 1996 Dec; 135(6):1003. PubMed ID: 8977729
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of prostaglandins and blockers of prostaglandin synthesis on the ductus arteriosus: animal and human studies.
    Heymann MA; Rudolph AM
    Adv Prostaglandin Thromboxane Res; 1978; 4():363-72. PubMed ID: 645512
    [No Abstract]   [Full Text] [Related]  

  • 27. [Management of pulmonary circulation alterations].
    Quero Jiménez MC; Burgueros Valero M; González Dieguez C; Domínguez Pérez F; Pinto Corraliza J; Rodríguez Fernández M
    Rev Esp Cardiol; 1993; 46 Suppl 2():13-28. PubMed ID: 7905203
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].
    Lillquist K
    Ugeskr Laeger; 1979 Jul; 141(28):1915-6. PubMed ID: 473414
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prostaglandin E, metabolic ligand with clinical and therapeutic implications in some congenital heart diseases and pulmonary diseases in infants].
    Olariu-Ungureanu A; Socaciu A; Săvulescu M; Stoica E; Atanasiu M; Velciu V
    Rev Pediatr Obstet Ginecol Pediatr; 1980; 29(1):23-32. PubMed ID: 6770437
    [No Abstract]   [Full Text] [Related]  

  • 30. Prostaglandin E1 in neonates with critical congenital heart disease.
    Dungan WT; Norton JB; Readinger RI; Sotomora RF
    J Ark Med Soc; 1982 Oct; 79(5):167-70. PubMed ID: 6183249
    [No Abstract]   [Full Text] [Related]  

  • 31. Postoperative ketotic hyperglycemia during prostaglandin E1 infusion in infancy.
    Cohen MH; Nihill MR
    Pediatrics; 1983 May; 71(5):842-4. PubMed ID: 6682218
    [No Abstract]   [Full Text] [Related]  

  • 32. Enteral feeding in neonates with prostaglandin-dependent congenital cardiac disease: international survey on current trends and variations in practice.
    Howley LW; Kaufman J; Wymore E; Thureen P; Magouirk JK; McNair B; da Cruz EM
    Cardiol Young; 2012 Apr; 22(2):121-7. PubMed ID: 21771388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Present state of therapy of congenital heart defects].
    Loogen F
    Dtsch Med J; 1967 Oct; 18(20):601-8. PubMed ID: 5610706
    [No Abstract]   [Full Text] [Related]  

  • 34. Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease.
    Yokota M; Muraoka R; Aoshima M; Nomoto S; Shiraishi Y; Kyoku I; Kitano M; Shimada I; Nakano H; Ueda K
    J Thorac Cardiovasc Surg; 1985 Sep; 90(3):399-403. PubMed ID: 4033176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandins and the management of congenital heart disease.
    Taylor WJ; Alpert BS
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Common congenital cyanotic heart defects--diagnosis and management.
    Ranjit MS
    J Indian Med Assoc; 2003 Feb; 101(2):71-2, 74. PubMed ID: 12841486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged prostaglandin E1 infusion in an infant with cyanotic congenital heart disease.
    Lewis AB; Lurie PR
    Pediatrics; 1978 Apr; 61(4):534-6. PubMed ID: 662477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn.
    Olley PM; Coceani F; Rowe RD; Swyer PR
    Adv Prostaglandin Thromboxane Res; 1980; 7():913-6. PubMed ID: 6768235
    [No Abstract]   [Full Text] [Related]  

  • 39. [Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus].
    Hruda J; Samánek M; First T; Vorísková M; Skovránek J
    Cesk Pediatr; 1985 May; 40(5):257-62. PubMed ID: 3860302
    [No Abstract]   [Full Text] [Related]  

  • 40. [The management of congenital heart diseases in childhood].
    Tikanoja T; Pesonen E
    Duodecim; 1996; 112(18):1613-5. PubMed ID: 10596153
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.